Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS)

Fukuoka, M.; Wu, Yi‐Cheng; Thongprasert, S.; Chih‐Hsin Yang, James; Chu, D.; Saijo, Nagahiro; Watkins, Cathy; Duffield, Emma; Armour, Alison; Mok, Tony

doi:10.1200/jco.2009.27.15_suppl.8006

Public

Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS)

Published in Journal of Clinical Oncology • May 20, 2009

Authors:

M. Fukuoka

Yi‐Cheng Wu

S. Thongprasert

Abstract

8006^ Background: IPASS demonstrated overall superiority of first-line G vs C/P for progression-free survival (PFS) in never/light ex-smokers with stage IIIB/IV adenocarcinoma NSCLC in Asia. PFS favored CP initially and then G. Outcome was correlated with biomarkers (preplanned exploratory objective...

Subject

Medicine

Internal medicine

Clinical endpoint

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!